Neuroscience and Behavior Program, Department of Psychology, University of Georgia, Athens, Georgia 30602-3013, USA.
AAPS J. 2010 Jun;12(2):147-57. doi: 10.1208/s12248-009-9170-8. Epub 2010 Feb 2.
Cannabinoid CB(2) receptors represent a therapeutic target that circumvents unwanted central side effects (e.g., psychoactivity and/or addiction) associated with activation of CB(1) receptors. One of the primary investigative tools used to study functions of the CB(2) receptor is the aminoalkylindole (R,S)-AM1241. However, (R,S)-AM1241 has been described as an atypical CB(2) agonist which produces antinociception mediated indirectly by opioid receptors. (R,S)-AM1241 and its enantiomers, (R)-AM1241 and (S)-AM1241, were evaluated for antinociception in response to thermal (Hargreaves) and mechanical (von Frey) stimulation. Pharmacological specificity was established using antagonists for CB(1) (rimonabant [SR141716]) and CB(2) (SR144528). The opioid antagonist naloxone was administered locally in the paw or systemically to evaluate the contribution of opioid receptors to CB(2)-mediated antinociception produced by (R,S)-AM1241, (R)-AM1241, and (S)-AM1241. Comparisons were made with the opioid analgesic morphine. (R,S)-AM1241, (R)-AM1241, and (S)-AM1241 (0.033-10 mg/kg i.p.) produced antinociception to thermal, but not mechanical, stimulation of the hindpaw in naive rats. Antinociception produced by (R,S)-AM1241 and (S)-AM1241 exhibited an inverted U-shaped dose response curve. (R)-AM1241 produced greater antinociception than either (S)-AM1241 or (R,S)-AM1241 at the lowest (0.033 and 0.1 mg/kg i.p.) and highest (10 mg/kg i.p.) doses. Similar levels of antinociception were observed at intermediate doses. (R,S)-AM1241, (R)-AM1241, and (S)-AM1241 each produced CB(2)-mediated antinociception that was blocked by SR144528 but not by rimonabant. Local and systemic naloxone blocked morphine-induced antinociception but did not block antinociceptive effects of (R,S)-AM1241, (R)-AM1241, or (S)-AM1241. The antinociceptive effects of the CB(2)-selective cannabinoid (R,S)-AM1241 and its enantiomers, (R)-AM1241 and (S)-AM1241, are not dependent upon opioid receptors.
大麻素 CB(2) 受体是一个治疗靶点,可以避免与 CB(1) 受体激活相关的中枢副作用(例如精神活性和/或成瘾)。研究 CB(2) 受体功能的主要研究工具之一是氨基酸吲哚 (R,S)-AM1241。然而,(R,S)-AM1241 被描述为一种非典型的 CB(2) 激动剂,它通过阿片受体间接产生镇痛作用。(R,S)-AM1241 及其对映异构体 (R)-AM1241 和 (S)-AM1241 用于评估对热 (Hargreaves) 和机械 (von Frey) 刺激的镇痛作用。使用 CB(1)(利莫那班 [SR141716])和 CB(2)(SR144528)的拮抗剂确定了药理学特异性。局部或全身给予阿片拮抗剂纳洛酮,以评估阿片受体对 (R,S)-AM1241、(R)-AM1241 和 (S)-AM1241 产生的 CB(2) 介导的镇痛作用的贡献。与阿片类镇痛药吗啡进行了比较。(R,S)-AM1241、(R)-AM1241 和 (S)-AM1241(0.033-10 mg/kg ip)对未处理大鼠的后爪热刺激产生镇痛作用,但对机械刺激无镇痛作用。(R,S)-AM1241 和 (S)-AM1241 的镇痛作用呈倒 U 形剂量反应曲线。(R)-AM1241 在最低(0.033 和 0.1 mg/kg ip)和最高(10 mg/kg ip)剂量下产生的镇痛作用大于 (S)-AM1241 或 (R,S)-AM1241。在中间剂量下观察到相似水平的镇痛作用。(R,S)-AM1241、(R)-AM1241 和 (S)-AM1241 均产生 CB(2) 介导的镇痛作用,该作用被 SR144528 阻断,但不受利莫那班阻断。局部和全身纳洛酮阻断吗啡诱导的镇痛作用,但不阻断 (R,S)-AM1241、(R)-AM1241 或 (S)-AM1241 的镇痛作用。CB(2) 选择性大麻素 (R,S)-AM1241 及其对映异构体 (R)-AM1241 和 (S)-AM1241 的镇痛作用不依赖于阿片受体。